What is Ipamorelin?
Ipamorelin is a more recently developed synthetic GHRP (growth hormone releasing peptide) that exhibits strong (GH) growth hormone releasing properties. In specific rats, Ipamorelin released GH with a potency and efficacy comparable to GHRP-6. The same study reported that Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH (adrenocorticotropic hormone) and cortisol. It was noted that ipamorelin did not release ACTH or cortisol in levels significantly different from those seen following GHRH administration, even at very high doses. This study concluded by saying that ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to GHRH, making it a very interesting candidate for future clinical development.
Ipamorelin research studies
Ipamorelin is a 3rd generation GHRP behind GHRP-6 and GHRP-2. Ipamorelin has very similar characteristics of GHRP-2: does not have ghrelin‘s lipogenic properties and does not promote hunger. Ipamorelin acts synergistically when applied during a Growth Hormone Releasing Hormone (GHRH) pulse or when it is administered along with a GHRH or an analog such as Sermorelin or Modified GRF 1-29 (growth releasing factor, aminos 1-29). The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHRH increases the number of somatotropes releasing GH. On the other hand, Ipamorelin is similar to GHRP-6 because they both release GH at a very similar strength minus the side effects that of GHRP-6. Both GHRP-6 and GHRP-2 cause a release and an increase in cortisol and prolactin levels, however Ipamorelin only selectively releases GH at any dose. Ipamorelin shares similar functionality to Hexarelin and compared to other peptides, it is a much more stable form of ghrelin and has longer half-life periods of at least two hours long and causes secondary effect by making neurons to become excited.
Ipamorelin has been shown to be both highly potent and very selective in vivo and vitro situations, and has also demonstrated good safety and tolerability in human clinical studies. Research has shown that Ipamorelin is growth hormone specific which means that the pituitary hormones such as cortisol are unaffected. In one study, it was found that young female adult mice had increased bone mass due to 12 weeks of treatment with ipamorelin.
Information is for educational/research purposes only. This is not medical advice.